Loading clinical trials...
Loading clinical trials...
A Multicentre, Prospective, Open-label Study With [68Ga]Ga-ABY-025 PET-imaging to Characterize HER2-expression and Explore the Therapy-predictive Value for HER2-antibody Drug Conjugates in Patients With Metastatic Breast Cancer
Conditions
Interventions
Positron emission tomografy with [68Ga]Ga-ABY-025
Locations
1
Sweden
Karolinska University hospital
Solna, Sweden
Start Date
October 3, 2025
Primary Completion Date
April 1, 2030
Completion Date
April 1, 2032
Last Updated
November 20, 2025
NCT07459673
NCT07446452
NCT06064812
NCT06533826
NCT06877416
NCT03324425
Lead Sponsor
Renske Altena
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions